Introduction
============

microRNAs (miRNAs) are involved in a variety of important biological behaviors including tumorigenesis, differentiation, apoptosis, and proliferation.[@b1-ott-9-3951],[@b2-ott-9-3951] It is widely accepted that miRNA polymorphisms can be used as biomarkers of tumor prognosis. For example, the miR-196a-2 rs11614913 polymorphism can predict the survival of several tumors, including gastric cancer (GC),[@b3-ott-9-3951],[@b4-ott-9-3951] non-small-cell lung cancer,[@b5-ott-9-3951],[@b6-ott-9-3951] esophageal squamous cell carcinoma,[@b7-ott-9-3951] oral squamous cell carcinoma,[@b8-ott-9-3951]--[@b10-ott-9-3951] kidney cancer,[@b11-ott-9-3951] and breast cancer.[@b12-ott-9-3951] The miR-27a rs895819 polymorphism can be used as a prognostic factor for advanced GC[@b4-ott-9-3951] and non-small-cell lung cancer.[@b13-ott-9-3951]

The let-7 plays a critical role in cell proliferation and differentiation; it is the earliest discovered miRNA and has continued to gain recognition in recent years. Several studies have proved that let-7 miRNA participates in the tumorigenesis and metastasis of different types of cancer, such as breast and lung cancers.[@b14-ott-9-3951]--[@b16-ott-9-3951] The let-7 family has ten members: let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let7i, miR-98, and miR-202. Recent research has linked polymorphisms of some let-7 family members to cancer, for example, the interaction of the pri-let-7a-1 rs10739971 polymorphism and the *ERCC6* rs1917799 polymorphism is significantly correlated with the risk of GC.[@b17-ott-9-3951] The rs10877887 polymorphism in the promoter region of let-7 is significantly associated with prognosis of hepatocellular carcinoma[@b18-ott-9-3951] and the pri-let-7a-2 rs629367 polymorphism is significantly related to poor survival of GC.[@b19-ott-9-3951] The relationship between the pri-let-7a-1 rs10739971 polymorphism and GC risk has been reported; however, few studies have investigated the association of the pri-let-7a-1 polymorphism and cancer prognosis. The relationship between the pri-let-7a-1 rs10739971 polymorphism and GC prognosis has not been reported.

In this study, systematic clinical data were collected for 334 cases of GC and the relationship between the pri-let-7a-1 rs10739971 polymorphism and cancer prognosis was investigated. We analyzed the effect of this polymorphism on mature let-7a expression both in serum and tissue. The aim of this study was to establish the relationship between this polymorphism and GC prognosis, and its possible mechanism.

Materials and methods
=====================

Patients and clinicopathological data
-------------------------------------

This study was approved by the Human Ethics Committee of the First Affiliated Hospital of China Medical University, and conformed to Chinese laws and the Helsinki Declaration. Written informed consent was obtained from the patients, and baseline characteristics (including age, sex, smoking, alcohol drinking, and family history) were obtained by questionnaire and the records above were computerized. Subjects were recruited who underwent gastric surgery in the First Affiliated Hospital of China Medical University, Liaoning Province, People's Republic of China between 2010 and 2013. Fasting venous blood was collected. Serum and blood coagulation were separated and stored at −20°C. All GC patients were diagnosed based on the histopathological confirmation according to Borrmann's as well as Lauren's classification, and the tumors were staged according to the 7th edition of the tumor node metastasis (TNM) staging system of the International Union Against Cancer/American Joint Committee on Cancer (2010), based on postoperative pathological examination. Exclusion criteria were 1) patients with distant metastasis found preoperatively; 2) patients who underwent preoperative radiotherapy or chemotherapy; or 3) patients with incomplete pathological data. Follow-up was completed by August 2013. The basic features of 334 GC patients enrolled in survival analysis are shown in [Table S1](#SD1-ott-9-3951){ref-type="supplementary-material"}.

To assess the effect of polymorphism on mature miRNA expression at the tissue level, 131 GC specimens from patients who underwent subtotal gastrectomy in the First Affiliated Hospital of China Medical University between 2010 and 2013 were included. At the serum level, we matched 99 GC patients with 99 healthy individuals. Patients who were endoscopically and histologically diagnosed with normal mucosa or only mild gastritis without other systemic diseases or other gastropathy served as controls. The basic information of all subjects is summarized in [Table S2](#SD2-ott-9-3951){ref-type="supplementary-material"}.

Single nucleotide polymorphism genotyping
-----------------------------------------

The genomic DNA was extracted using the method stated previously with proteinase K digestion and phenol/chloroform extraction.[@b20-ott-9-3951] Sequenom MassARRAY platform method (Sequenom, San Diego, CA, USA) and polymerase chain reaction (PCR) restriction-fragment length polymorphism were used to detect the polymorphism of pri-let-7a-1 rs10739971 G→A. To assess the quality of the genotyping, 5% samples of all were genotyped repeatedly and the results were 100% consistent.

RNA extraction and real-time quantitative PCR reaction for miRNA expression in vivo
-----------------------------------------------------------------------------------

miRNAs were extracted from the serum and tissues as described previously,[@b21-ott-9-3951] with some modifications. One Step Prime Script miRNA cDNA (Perfect Real Time) Kit (TaKaRa Biotechnology, Dalian, People's Republic of China) was used in the reverse transcription reaction and miRcute miRNA qPCR detection kit SuperReal PreMix Plus (SYBR) (Tiangen Biotech, Beijing, People's Republic of China) was used for real-time quantitative PCR. Details of the materials are shown in the Supplementary materials.

Statistical analysis
--------------------

All the statistical analyses were carried out using SPSS Version 16.0 software (SPSS Inc., Chicago, IL, USA). Correlation between the pri-let-7a-1 rs10739971 polymorphism and clinicopathological parameters of GC was estimated by *χ*^2^ test. Survival curves were estimated by the Kaplan--Meier method, and the association between the single nucleotide polymorphism (SNP) and different survival times was assessed by the log-rank test. The median survival time was calculated; the hazard ratios (HRs) and their 95% confidence intervals (CIs) were estimated by univariate and multivariate Cox proportional hazards regression models. The log value of copies of miRNA were used to reach a normal distribution, and the effect of miRNA polymorphisms on the expression level was tested by the independent-samples *t*-test, with the mean and standard deviation calculated.

Results
=======

Characteristics and clinical features of the study subjects
-----------------------------------------------------------

The demographic and clinical features of the 334 patients enrolled in this study are shown in [Table S1](#SD1-ott-9-3951){ref-type="supplementary-material"}, including age, sex, tumor size, Borrmann type, Lauren classification, TNM stage, growth pattern, lymphatic metastasis, smoking, alcohol consumption, and family history. Tumor size, Lauren grade, TNM stage, growth pattern, and lymphatic metastasis significantly affected survival time (*P*\<0.05). Therefore, we used these as adjustment factors for a multivariate Cox proportional hazards regression model.

Correlation between the pri-let-7a-1 rs10739971 polymorphism and clinicopathological parameters of GC
-----------------------------------------------------------------------------------------------------

The correlation between the pri-let-7a-1 rs10739971 polymorphism and clinicopathological parameters of GC was analyzed, including age, sex, tumor size, Borrmann type, Lauren classification, TNM stage, growth pattern, lymphatic metastasis, smoking, alcohol consumption, and family history. AA genotype was more frequent in the lymphatic-metastasis-negative subgroup than in the subgroup with lymphatic metastasis (52.5% vs 31.6%, *P*=0.009; 25.2% vs 14.6%, *P*=0.015). There was no significant correlation between the pri-let-7a-1 rs10739971 polymorphism and other clinicopathological parameters of GC ([Table 1](#t1-ott-9-3951){ref-type="table"}).

Association of the pri-let-7a-1 rs10739971 polymorphism with survival time of GC patients
-----------------------------------------------------------------------------------------

We analyzed the association of the pri-let-7a-1 rs10739971 polymorphism with prognosis of GC using a univariate Cox proportional hazards regression model. The log-rank test showed that survival time in patients with the AA or GA+AA genotype was significantly longer than in those with GG genotype (*P*=0.099, *P*=0.092, respectively; [Table 2](#t2-ott-9-3951){ref-type="table"}). Multivariate Cox proportional hazards regression model analysis showed that survival time was longer in patients with the variant AA genotype polymorphism (HR =0.75, *P*=0.762; [Table 2](#t2-ott-9-3951){ref-type="table"}), with adjustment for potential confounding factors, such as tumor size, Lauren classification, TNM stage, growth pattern, and lymphatic metastasis.

Stratified analysis of the effect of the pri-let-7a-1 rs10739971 polymorphism on survival time of GC patients
-------------------------------------------------------------------------------------------------------------

To evaluate the influence of different factors on the relationship between the pri-let-7a-1 rs10739971 polymorphism and GC patients' survival, we performed stratification analysis. This polymorphism was significantly associated with prognosis of GC in certain subgroups: survival time of subjects with AA or GA+AA genotype was significantly longer compared with those with wild-type GG genotype, especially in female patients (HR =0.24, 95% CI =0.07--0.86; HR =0.40, 95% CI =0.19--0.83; [Table 3](#t3-ott-9-3951){ref-type="table"}, [Figure 1A--D](#f1-ott-9-3951){ref-type="fig"}) and Borrmann type I/II patients (HR =0.44, 95% CI =0.20--0.94; HR =0.42, 95% CI =0.21--0.84; [Table 3](#t3-ott-9-3951){ref-type="table"}, [Figure 1E--H](#f1-ott-9-3951){ref-type="fig"}).

Effect of the pri-let-7a-1 rs10739971 polymorphism on mature let-7a expression
------------------------------------------------------------------------------

To study the possible mechanism of pri-let-7a-1 rs10739971 polymorphism in the survival time of GC patients, we further analyzed the effect of this polymorphism on its mature miRNA expression in serum and tissue. There was no significant difference for age and sex in all subjects (including GC patients and healthy controls, [Tables S2](#SD2-ott-9-3951){ref-type="supplementary-material"} and [S3](#SD3-ott-9-3951){ref-type="supplementary-material"}). In serum, mature let-7a expression of this polymorphism in healthy controls with the GA heterozygote and GA+AA genotype showed a significant increase compared with healthy people with the wild-type GG genotype (GA vs GG, *P*=0.028; GA+AA vs GG, *P*=0.018; [Table 4](#t4-ott-9-3951){ref-type="table"} and [Figure 2A](#f2-ott-9-3951){ref-type="fig"}). Mature let-7a expression in healthy women with this polymorphism (GA+AA) was significantly higher than those with GG genotype (GA+AA vs GG, *P*=0.043; [Table 4](#t4-ott-9-3951){ref-type="table"} and [Figure 2B](#f2-ott-9-3951){ref-type="fig"}). In GC patients, however, this polymorphism had no significant effect on its mature miRNA expression in serum or tissue ([Tables 4](#t4-ott-9-3951){ref-type="table"} and [5](#t5-ott-9-3951){ref-type="table"}).

Discussion
==========

We reported the relationship of the pri-let-7a-1 rs10739971 polymorphism with the prognosis of GC patients in Northern China. Cox proportional hazards regression model analysis showed that AA mutation genotype and GA+AA genotype correlated with GC prognosis (*P*\<0.10), especially in female patients or Borrmann type I/II patients. Further analysis found that AA mutation genotype was significantly correlated with lymphatic metastasis. After analyzing the effect of this polymorphism on its mature miRNA expression in serum and tissue, we found that mature miRNA expression of GA and GA+AA genotype was significantly higher than wild-type GG miRNA expression in the serum of all healthy people and the female healthy controls.

The miRNA polymorphism can act directly (including primary, secondary precursor, and mature polymorphism, which can affect maturation or function of miRNA) or indirectly (promoter region polymorphism affects the transcription and polymorphism-binding sites of the target gene). The pri-let-7a-1 rs10739971 polymorphism is located in -599 bp of mature let-7a-1, which is the primary precursor area of let-7a-1 and may also be the promoter region. We found that carriers of the variant genotype of this polymorphism demonstrated favorable prognosis compared with those with the wild genotype. The relationship between pri-let-7a-1 rs10739971 polymorphism and GC prognosis might arise from that this polymorphism is located at the promoter region. We adopted RNAfold software to predict secondary structure of the let-7a-1 gene near ±600 bp. The minimum free energy of those who carry the rs10739971 variant A allele was lower than that of those who carry the rs10739971 wild G allele. Furthermore, the secondary structure of miRNA with rs10739971 variant A allele tended to be more stable. Therefore, we speculated that the different structure of the rs10739971 G/A polymorphism may lead to a difference in function, because the variant A allele had a more stable secondary structure, which may be more conducive to the maturation process of miRNA. In addition, let-7a is recognized as a tumor suppressor, which might have a positive effect on tumor prognosis. GC patients who carry the variant A allele demonstrated longer survival. The wild-type G allele has a loose secondary structure, which may not be conductive to miRNA maturation, leading to a shorter survival time of GC patients who carry the wild-type G allele. We also found that the rate of lymphatic metastasis in GC patients with the AA mutation genotype was significantly lower than in those with wild GG genotype. This was consistent with our finding that patients with the AA mutation genotype exhibited significantly longer survival time than those with the wild GG genotype. Lymphatic metastasis is a risk factor for GC; thus, we consider that the significantly longer survival time observed for carriers of the AA mutation genotype may be related to the absence of lymphatic metastasis.

Stratified analysis suggested that female patients who carry this polymorphism AA or GA+AA genotype had significantly longer survival. The let-7 is a direct estrogen receptor (ER)-α target gene, and its expression correlates with ER-α in breast, ovarian, and gastric cancer, and it inhibits cancer cell proliferation and promotes cancer cell apoptosis.[@b15-ott-9-3951],[@b22-ott-9-3951],[@b23-ott-9-3951] Previous studies showed that let-7 is an important regulator of ER-α target genes and it shares many binding sites with ER-α. Notably, at shared sites, let-7 inhibits the ER-α signaling pathway, which decreases the survival of cancer cells and increases their rate of apoptosis.[@b14-ott-9-3951],[@b15-ott-9-3951] As a result, in female patients with more ER-α, more let-7 polymorphisms, which act as a protective factor, contribute to better prognosis. We speculated that female GC patients who carried variant A allele had increased expression of mature let-7a compared with G allele carriers, which could more efficiently inhibit tumor cell proliferation and induce tumor cell apoptosis, thereby leading to longer survival time. However, the result was not what we expected: expression of mature let-7a was not increased significantly in GC patients with the variant A allele. The binding of mature let-7a and ER-α is due to the variant A allele, which may lead to the result above. In stratified analysis, we also found that Borrmann type I/II patients who carry this polymorphism of GA heterozygous or (GA+AA) genotype demonstrated more favorable prognosis than GG genotype subjects. Yang found that the Borrmann type is an independent prognostic factor only in stage IV GC,[@b24-ott-9-3951] which showed that it has an important role in GC prognosis. rs10739971 is located in the promoter region of let-7a miRNA, which might affect the post-transcriptional regulation of let-7a miRNA, through the binding of different transcription factors. We conjectured that rs10739971 could affect the Borrmann type through its effect on the expression of mature let-7a. Moreover, the phenomenon that the A allele of this polymorphism was related to favorable prognosis may be because the effect of the variant A allele is great in the case of healthy individuals and patients with primary stage GC. Besides, we found that survival time was not significantly longer in men with AA or GA+AA genotypes and in Borrmann type III/IV patients with GA heterozygote of GA+AA genotypes, which suggest that sex and Borrmann classification might influence the effect of SNP on GC survival.

Mature miRNA is part of the regulatory mechanisms controlling gene expression at both transcriptional and post-transcriptional levels. According to recent research,[@b25-ott-9-3951] one miRNA can regulate the expression of multiple genes, while a single gene is regulated by a series of different miRNAs, and \~60% of protein-coding genes are regulated by miRNAs. At present, research about the pathogenic mechanism of the miRNA promoter region polymorphism has mainly focused on the functional miR-34b/c rs4938723 polymorphism. This polymorphism might affect the binding ability of transcription factor GATA and further influence mature pri-miR-34b/c expression.[@b26-ott-9-3951] Xu et al thought it may serve as biomarker of liver cancer prognosis. We speculated that the significant association of the pri-let-7a-1 rs10739971 polymorphism with the prognosis of GC may arise from the influence of mature let-7a expression, like the miR-34b/c rs4938723 polymorphism. Therefore, we explored further the effect of this polymorphism on its mature miRNA expression level. In serum, we found that mature let-7a expression in healthy individuals with the GA heterozygote and GA+AA genotype showed a significant increase, and mature let-7a expression in healthy women with the GA+AA genotype was significantly higher. This indicated that the variant A allele was beneficial to let-7a miRNA maturation, illustrating that the miRNA polymorphism acts as a tumor suppressor by increasing the expression of mature miRNA, which is consistent with the effect of the miR-34b/c rs4938723 polymorphism on the expression of its maturity.[@b26-ott-9-3951] In tissue, we found that mature let-7a expression in individuals with different genotypes showed no significant difference between the GC and healthy groups, which may be because the tissue of the healthy group was taken from distal GC patients instead of really healthy people. In GC patients, no significant effect of this polymorphism on its mature miRNA expression, either in serum or tissue, was observed. The following reasons may explain the results. First, the state of disease (cancerous) disturbs multiple cellular functions and regulations, which probably weaken the effect of the miRNA SNP on mature miRNA expression. Second, the sample size of expression study was relatively small, which might restrict the results and should be confirmed in a larger sample of future investigation. In addition, it should be further researched that whether other cofactors also affect let-7a expression together with SNP.

In summary, this study analyzed the association of the pri-let-7a-1 rs10739971 polymorphism and GC prognosis stratified by clinicopathological parameters on the basis of overall analysis. We preliminarily studied the effect of the pri-let-7a-1 rs10739971 polymorphism on the expression level of miRNA to explore the possible mechanism of the effect of miRNA polymorphism on GC prognosis. This is believed to be the first study exploring the relationship between the pri-let-7a-1 rs10739971 G/A polymorphism and GC prognosis in Northern China. There were some limitations to our study. First, the sample size was insufficient, and our results need validation with a larger sample of different ethnicities. Second, our study only investigated overall survival time, and other relevant indicators of prognosis research need to be explored, such as disease-free survival time. Third, subsequent experiments concerning function of miRNA are still needed.

Conclusion
==========

The pri-let-7a-1 rs10739971 polymorphism has potential as a prognostic biomarker of GC, especially for female and Borrmann type I/II patients. The pri-let-7a-1 rs10739971 polymorphism might affect serum mature let-7a expression, which might partly explain the mechanism of the pri-let-7a-1 rs10739971 polymorphism in GC survival. Future large-sample studies and mechanism experiments are needed to prove our findings.

Supplementary materials
=======================

Serum RNA extraction and real-time quantitative PCR reaction for miRNA expression in vivo
-----------------------------------------------------------------------------------------

Approximately 6 mL venous blood was collected from each subject. Serum total RNA was extracted using a method described by Liu et al[@b27-ott-9-3951] with some modifications. Serum was separated by centrifugation at 3,000× *g* for 10 minutes, followed by a 15 minutes high-speed centrifugation at 12,000× *g* to completely remove cell debris. The supernatant serum was recovered and stored at −80°C until further processing. Total RNA was extracted from 200 μL of serum by acid phenol/chloroform purification and centrifugation in isopropyl alcohol. Every sample was all in 20 μL RNA-free ddH~2~O solution and 6 μL of total RNA was reverse-transcribed to cDNA using One Step PrimeScript miRNA cDNA Synthesis Kit (TaKaRa Biotechnology, Dalian, People's Republic of China). Real-time PCR was performed using a miRcute miRNA qPCR detection kit (Tiangen Biotech, Beijing, People's Republic of China) on the Thermal Cycler Dice Real Time System (TaKaRa Biotechnology). To calculate the levels of the miRNAs, synthetic hsa-let-7a at known concentrations (TaKaRa Biotechnology) were also reverse-transcribed and amplified. The concentration of each miRNA was then calculated according to the standard curve. All reactions, including no-template controls, were run in duplicate.

###### 

Clinical features of gastric cancer patients

  Variables               GC patients N=334 (%)   Death N=92   MST (M)                                           Log-rank       
  ----------------------- ----------------------- ------------ ------------------------------------------------- -------------- --------------------------
  Age (years)                                                                                                                   
   ≤59                    184 (55.1)              54           55.8[a](#tfn11-ott-9-3951){ref-type="table-fn"}                  1 (Ref)
   \>59                   150 (44.9)              38           59.1[a](#tfn11-ott-9-3951){ref-type="table-fn"}   0.852          0.96 (0.64--1.46)
  Sex                                                                                                                           
   Male                   244 (73.1)              63           61.7[a](#tfn11-ott-9-3951){ref-type="table-fn"}                  1 (Ref)
   Female                 90 (26.9)               29           43.3[a](#tfn11-ott-9-3951){ref-type="table-fn"}   0.339          0.81 (0.52--1.25)
  Size (cm)                                                                                                                     
    ≤4                    48 (14.4)               1            27.3[a](#tfn11-ott-9-3951){ref-type="table-fn"}                  1 (Ref)
   .4                     56 (16.8)               15           13.0                                              **0.009**      **15.24 (1.99--116.80)**
  Borrmann type                                                                                                                 
   Borrmann I--II         176 (65.9)              45           44.0                                                             1 (Ref)
   Borrmann III--IV       91 (34.1)               33           59.3[a](#tfn11-ott-9-3951){ref-type="table-fn"}   0.810          1.06 (0.67--1.67)
  Lauren classification                                                                                                         
   Intestinal             110 (32.9)              20           63.3[a](#tfn11-ott-9-3951){ref-type="table-fn"}                  1 (Ref)
   Diffuse                214 (64.1)              66           57.3[a](#tfn11-ott-9-3951){ref-type="table-fn"}   **0.031**      **1.74 (1.05--2.86)**
   Unclassified           10 (3.0)                2                                                                             
  TNM stage                                                                                                                     
   I--III                 300 (89.8)              72           58.9[a](#tfn11-ott-9-3951){ref-type="table-fn"}                  1 (Ref)
   IV                     34 (10.2)               20           20.0                                              **1×10^−6^**   **3.46 (2.10--5.69)**
  Growth pattern                                                                                                                
   Massive and Nested     110 (32.9)              15           34.7[a](#tfn11-ott-9-3951){ref-type="table-fn"}                  1 (Ref)
   Diffused               145 (43.4)              44           26.6[a](#tfn11-ott-9-3951){ref-type="table-fn"}   **1×10^−4^**   **3.21 (1.78--5.80)**
  Lymphatic metastasis                                                                                                          
   Negative               128 (38.3)              14           70.7[a](#tfn11-ott-9-3951){ref-type="table-fn"}                  1 (Ref)
   Positive               206 (61.7)              78           44.0                                              **1×10^−6^**   **4.06 (2.30--7.18)**
  Smoking                                                                                                                       
   Nonsmoker              158 (47.3)              35           30.5[a](#tfn11-ott-9-3951){ref-type="table-fn"}                  1 (Ref)
   Smoker                 96 (28.7)               24           29.9[a](#tfn11-ott-9-3951){ref-type="table-fn"}   0.843          1.05 (0.63--1.77)
  Alcohol drinking                                                                                                              
   Nondrinker             164 (49.1)              39           30.2[a](#tfn11-ott-9-3951){ref-type="table-fn"}                  1 (Ref)
   Drinker                91 (27.2)               20           30.6[a](#tfn11-ott-9-3951){ref-type="table-fn"}   0.547          0.81 (0.40--1.63)
  Family history                                                                                                                
   No                     216 (64.7)              54           29.7[a](#tfn11-ott-9-3951){ref-type="table-fn"}                  1 (Ref)
   Yes                    39 (11.7)               5            34.9[a](#tfn11-ott-9-3951){ref-type="table-fn"}   0.584          0.86 (0.50--1.48)

**Notes:**

Mean survival time was provided when MST could not be calculated. The significant results marked in bold.

**Abbreviations:** CI, confidence interval; HR, hazard ratio; GC, gastric cancer; MST, median survival time; M, month; Ref, reference.

###### 

The basic characteristics of the subjects included to investigate the association of pri-let-7a-1 rs10739971 polymorphism with its mature miRNA expression in serum or tissue of gastric cancer

  Variables     Serum         Tissue        
  ------------- ------------- ------------- -------------
  Sex           *P*=0.766                   
   Male         63 (63.64)    65 (65.66)    46 (35.11)
   Female       36 (36.36)    34 (34.34)    85 (64.89)
  Age (years)   *P*=0.657                   
   Mean ± SD    59.56±11.19   60.67±11.14   59.18±11.57
   Median       60            62            59
   Range        23--81        27--80        30--87

**Abbreviations:** CON, control; GC, gastric cancer; miRNA, microRNA; SD, standard deviation.

###### 

Independent-samples *t*-test for the effect of pri-let-7a-1 rs10739971 polymorphism to its mature miRNA expression in serum level and in tissue level

  Variables                   GG   GA          AA                                                    
  --------------------------- ---- ----------- --------- ---- ----------- --------- ---- ----------- ---------
  Serum expression                                                                                   
   Total                                                                                             
    CON                       28   3.18±0.57   1 (Ref)   54   3.64±0.53   1 (Ref)   17   3.45±0.43   1 (Ref)
    GC                        31   3.33±0.64   0.325     54   3.39±0.50   0.881     14   3.27±0.53   0.303
   Male                                                                                              
    CON                       17   3.22±0.61   1 (Ref)   35   3.49±0.59   1 (Ref)   11   3.43±0.51   1 (Ref)
    GC                        19   3.32±0.64   0.636     37   3.45±0.53   0.757     9    3.28±0.59   0.535
   Female                                                                                            
    CON                       11   3.11±0.51   1 (Ref)   35   3.41±0.41   1 (Ref)   11   3.49±0.28   1 (Ref)
    GC                        12   3.35±0.66   0.336     37   3.28±0.44   0.368     9    3.25±0.49   0.35
  Tissue expression in situ                                                                          
   Total                                                                                             
    CON                       33   5.48±0.51   1 (Ref)   40   5.38±0.82   1 (Ref)   16   5.20±0.72   1 (Ref)
    GC                        40   5.43±0.69   0.709     46   5.41±0.72   0.881     18   5.14±0.59   0.787
   Male                                                                                              
    CON                       21   5.55±0.44   1 (Ref)   28   5.46±0.77   1 (Ref)   11   5.24±0.84   1 (Ref)
    GC                        25   5.34±0.67   0.226     34   5.42±0.75   0.814     13   5.19±0.66   0.877
   Female                                                                                            
    CON                       12   5.36±0.63   1 (Ref)   12   5.19±0.92   1 (Ref)   5    5.12±0.42   1 (Ref)
    GC                        15   5.57±0.73   0.439     12   5.37±0.65   0.577     5    5.01±0.40   0.677

**Abbreviations:** CON, control; GC, gastric cancer; SD, standard deviation; Ref, reference.
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![Kaplan--Meier survival curve analysis with the different genotypes of pri-let-7a-1 rs10739971 in different subgroups.\
**Notes:** (**A**) AA vs GG in male subgroup. (**B**) GA+AA vs GG in male subgroup. (**C**) AA vs GG in female subgroup. (**D**) GA+AA vs GG in female subgroup. (**E**) GA vs GG in Borrmann I--II subgroup. (**F**) GA+AA vs GG in Borrmann I--II subgroup. (**G**) GA vs GG in Borrmann III--IV subgroup. (**H**) GA+AA vs GG in Borrmann III--IV subgroup.](ott-9-3951Fig1){#f1-ott-9-3951}

![The effect of pri-let-7a-1 rs10739971 G/A SNP on the mature let-7a expression.\
**Notes:** (**A**) The let-7a expression of different genotype of pri-let-7a-1 rs10739971 in healthy people serum. (**B**) The let-7a expression of different genotype of pri-let-7a-1 rs10739971 in healthy female serum.](ott-9-3951Fig2){#f2-ott-9-3951}

###### 

Correlation between pri-let-7a-1 rs10739971 polymorphism and clinicopathological parameters in gastric cancer

  Variables               GG   GA    *P*~adjustment~[a](#tfn1-ott-9-3951){ref-type="table-fn"}   AA   *P*~adjustment~[a](#tfn1-ott-9-3951){ref-type="table-fn"}   *P*~adjustment~[a](#tfn1-ott-9-3951){ref-type="table-fn"}   *P*~adjustment~[a](#tfn1-ott-9-3951){ref-type="table-fn"}
  ----------------------- ---- ----- ----------------------------------------------------------- ---- ----------------------------------------------------------- ----------------------------------------------------------- -----------------------------------------------------------
  Size (cm)                          0.690                                                            0.980                                                       0.762                                                       0.775
   ≤4                     15   25                                                                8                                                                                                                            
   \>4                    16   32                                                                8                                                                                                                            
  Borrmann type                      0.228                                                            0.636                                                       0.444                                                       0.203
   Borrmann I--II         29   42                                                                20                                                                                                                           
   Borrmann III--IV       48   100                                                               28                                                                                                                           
  Lauren classification              0.872                                                            0.428                                                       0.870                                                       0.294
   Intestinal             32   61                                                                17                                                                                                                           
   Diffuse                60   109                                                               45                                                                                                                           
  TNM stage                          0.737                                                            0.872                                                       0.819                                                       0.803
   I--III                 86   158                                                               56                                                                                                                           
   IV                     9    19                                                                6                                                                                                                            
  Growth pattern                     0.547                                                            0.632                                                       0.513                                                       0.733
   Massive and nested     33   60                                                                17                                                                                                                           
   Diffused               38   81                                                                26                                                                                                                           
  Lymphatic metastasis               0.298                                                            0.010[b](#tfn2-ott-9-3951){ref-type="table-fn"}             0.095                                                       0.023[b](#tfn2-ott-9-3951){ref-type="table-fn"}
   Negative               29   111                                                               32                                                                                                                           
   Positive               65   66                                                                30                                                                                                                           
  Smoking                            0.964                                                            0.782                                                       0.981                                                       0.915
   Nonsmoker              45   86                                                                26                                                                                                                           
   Smoker                 26   55                                                                17                                                                                                                           
  Alcohol drinking                   0.251                                                            0.141                                                       0.169                                                       0.307
   Nondrinker             53   92                                                                25                                                                                                                           
   Drinker                18   49                                                                18                                                                                                                           
  Family history                     0.495                                                            0.271                                                       0.358                                                       0.396
   No                     58   120                                                               38                                                                                                                           
   Yes                    13   21                                                                5                                                                                                                            

**Notes:**

*P*~adjustment~: using logistic regression adjusted by two factors of sex and age;

*P*=0.010, OR (95% CI) =0.41 (0.21--0.81); *P*=0.023, OR (95% CI) =0.52(0.30--0.91).

**Abbreviations:** CI, confidence interval; OR, odds ratio.

###### 

Univariate and multivariate Cox proportional hazard analysis for pri-let-7a-1 rs10739971 polymorphism

  Variables     All GC   Death   MST (M)                                          Univariate   Multivariate                
  ------------- -------- ------- ------------------------------------------------ ------------ ------------------- ------- -------------------
  rs10739971                                                                                                               
   GG           95       31      44                                                            1 (Ref)                     1 (Ref)
   GA           177      46      62.0[a](#tfn4-ott-9-3951){ref-type="table-fn"}   0.169        0.73 (0.46--1.15)   0.563   1.48 (0.39--5.65)
   AA           62       15      51.0[a](#tfn4-ott-9-3951){ref-type="table-fn"}   0.099        0.59 (0.32--1.10)   0.762   0.75 (1.12--4.69)
  GA+AA vs GG                                                                     0.092        0.69 (0.45--1.06)   0.677   1.32 (0.36--4.80)
  AA vs GG+GA                                                                     0.269        0.73 (0.42--1.27)   0.580   0.66 (0.15--2.88)

**Note:**

Mean survival time was provided when MST could not be calculated.

**Abbreviations:** CI, confidence interval; GC, gastric cancer; HR, hazard ratio; MST, median survival time; M, month; Ref, reference.

###### 

Stratified analysis for the association of pri-let-7a-1 rs10739971 genotypes and gastric cancer survival

  Variables               Death/patients   GA vs GG    AA vs GG                GA+AA vs GG   AA vs GA+GG                                                         
  ----------------------- ---------------- ----------- ----------------------- ------------- ----------------------- ----------- ----------------------- ------- --------------------
  Age (years)                                                                                                                                                    
   ≤59                    54/184           0.122       0.61 (0.33--1.14)       0.429         0.75 (0.36--1.54)       0.144       0.65 (0.37--1.16)       0.933   1.03 (0.55--1.92)
   \>59                   38/150           0.676       0.87 (0.44--1.70)       0.052         0.23 (0.05--1.01)       0.315       0.71 (0.37--1.38)       0.065   0.26 (0.06--1.09)
  Sex                                                                                                                                                            
   Male                   63/244           0.779       0.92 (0.52--1.64)       0.686         0.86 (0.41--1.79)       0.724       0.91 (0.52--1.57)       0.771   0.91 (0.49--1.71)
   Female                 29/90            0.056       0.47 (0.22--1.02)       **0.028**     **0.24 (0.07--0.86)**   **0.014**   **0.40 (0.19--0.83)**   0.121   0.39 (0.12--1.29)
  Size (cm)                                                                                                                                                      
   ≤4                     1/48             0.595       NA                      0.650         NA                      0.581       NA                      0.737   NA
   \>4                    15/56            0.514       1.55 (0.42--5.78)       0.904         1.12 (0.19--6.70)       0.602       1.41 (0.39--5.06)       0.678   0.73 (0.16--3.28)
  Borrmann type                                                                                                                                                  
   Borrmann I--II         45/176           **0.033**   **0.44 (0.20--0.94)**   0.065         0.41 (0.16--1.06)       **0.015**   **0.42 (0.21--0.84)**   0.310   0.63 (0.26--1.53)
   Borrmann III--IV       33/91            0.334       0.72 (0.36--1.41)       0.690         0.84 (0.35--2.02)       0.356       0.74 (0.39--1.41)       0.872   1.07 (0.50--2.29)
  Lauren classification                                                                                                                                          
   Intestinal             20/110           0.687       0.83 (0.33--2.10)       0.099         0.17 (0.02--1.39)       0.346       0.64 (0.26--1.61)       0.108   0.19 (0.03--1.44)
   Diffuse                66/214           0.162       0.68 (0.39--1.17)       0.373         0.74 (0.38--1.44)       0.159       0.69 (0.42--1.16)       0.864   0.95 (0.53--1.71)
  TNM stage                                                                                                                                                      
   I--III                 72/300           0.108       0.65 (0.39--1.10)       0.298         0.71 (0.37--1.36)       0.102       0.67 (0.41--1.08)       0.778   0.92 (0.51--1.65)
   IV                     20/34            0.881       0.93 (0.35--2.46)       0.080         0.15 (0.02--1.26)       0.497       0.72 (0.27--1.88)       0.098   0.18 (0.02--1.37)
  Growth pattern                                                                                                                                                 
   Massive and nested     15/110           0.063       0.49 (0.23--1.04)       0.743         0.76 (0.15--3.94)       0.782       0.86 (0.29--2.52)       0.748   0.78 (0.18--3.48)
   Diffused               44/145           0.624       0.84 (0.42--1.68)       0.404         0.671 (0.26--1.71)      0.489       0.79 (0.41--1.54)       0.475   0.75 (0.33--1.67)
  Lymphatic metastasis                                                                                                                                           
   Negative               14/128           0.588       0.71 (0.21--2.43)       0.479         0.58 (0.13--2.60)       0.495       0.67 (0.21--2.13)       0.636   0.74 (0.21--2.63)
   Positive               78/206           0.327       0.78 (0.48--1.28)       0.469         0.78 (0.39--1.54)       0.297       0.78 (0.49--1.25)       0.761   0.91 (0.49--1.68)
  Smoking                                                                                                                                                        
   Nonsmoker              35/158           0.447       0.76 (0.38--1.54)       0.108         0.36 (0.10--1.25)       0.225       0.65 (0.33--1.30)       0.138   0.41 (0.13--1.33)
   Smoker                 24/96            0.528       1.43 (0.47--4.36)       0.313         1.92 (0.54--6.81)       0.420       1.56 (0.53--4.46)       0.398   1.49 (0.59--3.75)
  Alcohol drinking                                                                                                                                               
   Nondrinker             39/164           0.948       0.98 (0.50--1.93)       0.344         0.55 (0.16--1.92)       0.744       0.90 (0.46--1.74)       0.332   0.56 (0.17--1.81)
   Drinker                20/91            0.714       0.80 (0.25--2.58)       0.876         0.90 (0.25--3.22)       0.759       0.842 (0.28--2.53)      0.876   1.08 (0.41--2.82)
  Family history                                                                                                                                                 
   No                     54/216           0.671       0.88 (0.48--1.60)       0.192         0.55 (0.23--1.35)       0.422       0.79 (0.44--1.41)       0.192   0.59 (0.27--1.30)
   Yes                    5/39             0.971       1.05 (0.10--11.55)      0.178         5.25 (0.47--58.60)      0.641       1.69 (0.19--15.08)      0.076   5.09 (0.84--30.78)

**Note:** The significant results marked in bold.

**Abbreviations:** CI, confidence interval; HR, hazard ratio; NA, not available.

###### 

Independent-samples *t*-test for the effect of pri-let-7a-1 rs10739971 polymorphism to its mature miRNA expression in serum level

  Variables     CON   GC                                       
  ------------- ----- ----------- ----------- ---- ----------- ---------
  Total                                                        
   GG           28    3.18±0.57   1 (Ref)     31   3.33±0.64   1 (Ref)
   GA           54    3.46±0.53   **0.028**   54   3.39±0.50   0.627
   AA           17    3.45±0.43   0.094       14   3.27±0.53   0.745
  GA+AA vs GG                     **0.018**                    0.769
  AA vs GA+GG                     0.541                        0.519
  Male                                                         
   GG           17    3.22±0.61   1 (Ref)     19   3.32±0.64   1 (Ref)
   GA           35    3.49±0.59   0.137       37   3.45±0.53   0.435
   AA           11    3.43±0.51   0.354       9    3.28±0.59   0.860
  GA+AA vs GG                     0.129                        0.553
  AA vs GA+GG                     0.875                        0.532
  Female                                                       
   GG           11    3.11±0.51   1 (Ref)     12   3.35±0.66   1 (Ref)
   GA           19    3.41±0.41   0.086       17   3.28±0.44   0.724
   AA           6     3.49±0.28   0.115       5    3.25±0.49   0.776
  GA+AA vs GG                     **0.043**                    0.683
  AA vs GA+GG                     0.345                        0.837

**Note:** The significant results marked in bold.

**Abbreviations:** CON, control; GC, gastric cancer; SD, standard deviation; Ref, reference.

###### 

Independent-samples *t*-test for the effect of pri-let-7a-1 rs10739971 polymorphism to its mature miRNA expression in tissue level

  Variables     CON   GC                                     
  ------------- ----- ----------- --------- ---- ----------- ---------
  Total                                                      
   GG           33    5.48±0.51   1 (Ref)   40   5.43±0.69   1 (Ref)
   GA           40    5.38±0.82   0.542     46   5.41±0.72   0.890
   AA           16    5.20±0.73   0.129     18   5.14±0.59   0.137
  GA+AA vs GG                     0.329                      0.496
  AA vs GA+GG                     0.253                      0.127
  Male                                                       
   GG           21    5.55±0.44   1 (Ref)   25   5.34±0.67   1 (Ref)
   GA           28    5.46±0.77   0.637     34   5.42±0.75   0.698
   AA           11    5.24±0.84   0.178     13   5.19±0.66   0.517
  GA+AA vs GG                     0.419                      0.946
  AA vs GA+GG                     0.262                      0.377
  Female                                                     
   GG           12    5.36±0.63   1 (Ref)   15   5.57±0.73   1 (Ref)
   GA           12    5.19±0.92   0.608     12   5.37±0.65   0.485
   AA           5     5.12±0.42   0.455     5    5.01±0.40   0.125
  GA+AA vs GG                     0.500                      0.244
  AA vs GA+GG                     0.674                      0.152

**Abbreviations:** CON, control; GC, gastric cancer; SD, standard deviation; Ref, reference.
